Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Elena Grassi

Showing results (41-50 of 49) with videos related to

Pageof 5
Sort By:
You have reached the last page of results.This site can display upto 49 results.
Science Translational Medicine|August 16, 2023
Phosphoproteomics of patient-derived xenografts identifies targets and markers associated with sensitivity and resistance to EGFR blockade in colorectal cancerRobin Beekhof, Andrea Bertotti, Franziska Böttger, et al.
ESMO Open|September 29, 2020
Pertuzumab and trastuzumab emtansine in patients with HER2-amplified metastatic colorectal cancer: the phase II HERACLES-B trialAndrea Sartore-Bianchi, Sara Lonardi, Cosimo Martino, et al.
Genome Medicine|October 10, 2024
DNA demethylation triggers cell free DNA release in colorectal cancer cellsValeria Pessei, Marco Macagno, Elisa Mariella, et al.
Nature Communications|August 29, 2024
XENTURION is a population-level multidimensional resource of xenografts and tumoroids from metastatic colorectal cancer patientsSimonetta M Leto, Elena Grassi, Marco Avolio, et al.
Science Translational Medicine|May 21, 2025
Heterogeneity and evolution of DNA mutation rates in microsatellite stable colorectal cancerElena Grassi, Valentina Vurchio, George D Cresswell, et al.
Science Translational Medicine|August 8, 2020
Colorectal cancer residual disease at maximal response to EGFR blockade displays a druggable Paneth cell-like phenotypeBarbara Lupo, Francesco Sassi, Marika Pinnelli, et al.
Cancer Discovery|September 22, 2025
The molecular and functional landscape of resistance to FOLFIRI chemotherapy in metastatic colorectal cancerMarco Avolio, Simonetta M Leto, Francesco Sassi, et al.
Nature Genetics|June 3, 2024
Author Correction: Pathway level subtyping identifies a slow-cycling biological phenotype associated with poor clinical outcomes in colorectal cancerSudhir B Malla, Ryan M Byrne, Maxime W Lafarge, et al.
Nature Genetics|February 14, 2024
Pathway level subtyping identifies a slow-cycling biological phenotype associated with poor clinical outcomes in colorectal cancerSudhir B Malla, Ryan M Byrne, Maxime W Lafarge, et al.
Pageof 5

Showing results (41-50 of 49) with videos related to

Sort By:
Pageof 5
You have reached the last page of results.This site can display upto 49 results.
Science Translational Medicine|August 16, 2023
Phosphoproteomics of patient-derived xenografts identifies targets and markers associated with sensitivity and resistance to EGFR blockade in colorectal cancerRobin Beekhof, Andrea Bertotti, Franziska Böttger, et al.
ESMO Open|September 29, 2020
Pertuzumab and trastuzumab emtansine in patients with HER2-amplified metastatic colorectal cancer: the phase II HERACLES-B trialAndrea Sartore-Bianchi, Sara Lonardi, Cosimo Martino, et al.
Genome Medicine|October 10, 2024
DNA demethylation triggers cell free DNA release in colorectal cancer cellsValeria Pessei, Marco Macagno, Elisa Mariella, et al.
Nature Communications|August 29, 2024
XENTURION is a population-level multidimensional resource of xenografts and tumoroids from metastatic colorectal cancer patientsSimonetta M Leto, Elena Grassi, Marco Avolio, et al.
Science Translational Medicine|May 21, 2025
Heterogeneity and evolution of DNA mutation rates in microsatellite stable colorectal cancerElena Grassi, Valentina Vurchio, George D Cresswell, et al.
Science Translational Medicine|August 8, 2020
Colorectal cancer residual disease at maximal response to EGFR blockade displays a druggable Paneth cell-like phenotypeBarbara Lupo, Francesco Sassi, Marika Pinnelli, et al.
Cancer Discovery|September 22, 2025
The molecular and functional landscape of resistance to FOLFIRI chemotherapy in metastatic colorectal cancerMarco Avolio, Simonetta M Leto, Francesco Sassi, et al.
Nature Genetics|June 3, 2024
Author Correction: Pathway level subtyping identifies a slow-cycling biological phenotype associated with poor clinical outcomes in colorectal cancerSudhir B Malla, Ryan M Byrne, Maxime W Lafarge, et al.
Nature Genetics|February 14, 2024
Pathway level subtyping identifies a slow-cycling biological phenotype associated with poor clinical outcomes in colorectal cancerSudhir B Malla, Ryan M Byrne, Maxime W Lafarge, et al.
Pageof 5